Iovance rises as FDA lifts partial clinical hold on lung cancer therapy trial

Iovance Biotherapeutics

04/03/2024 12:17

** Shares of Iovance Biotherapeutics  IOVA.O  up 8.7% at
$18.30 premarket 
    ** Co reported U.S. FDA has lifted a partial clinical hold
placed on registrational trial of its experimental cell therapy
for a type of lung cancer 
    ** The clinical hold was placed by the agency last year
nearing December end, after a patient death
    ** The therapy, called LN-145 TIL, uses white blood cells
from a patient's tumor, modifies them and puts them back into
the patient to help the immune system destroy cancer cells 
    ** In collaboration with the FDA and an independent data
monitoring committee, co said it developed additional safety
measures and monitoring
    ** Upon reviewing this proposal, the FDA has cleared Iovance
to resume patient enrollment in the trial 
    ** IOVA expects to complete enrollment of about 120 patients
in the registrational cohorts in 2025 
    ** As of last close, stock up 106.52% YTD 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))